# Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis

> **NCT06453317** · PHASE2 · RECRUITING · sponsor: **Medical University of Lodz** · enrollment: 172 (estimated)

## Conditions studied

- Ulcerative Colitis
- Inflammatory Bowel Diseases

## Interventions

- **BIOLOGICAL:** Infliximab
- **BIOLOGICAL:** Ustekinumab

## Key facts

- **NCT ID:** NCT06453317
- **Lead sponsor:** Medical University of Lodz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06453317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06453317, "Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06453317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*